Literature DB >> 8968556

Mediation by nitric oxide of the indirect effects of adenosine on calcium current in rabbit heart pacemaker cells.

Y Shimoni1, X Han, D Severson, W R Giles.   

Abstract

1. Adenosine (ADO) is a potent negative chronotropic agent in the mammalian myocardium. We have used single myocytes from rabbit sino-atrial node (SAN) to examine whether nitric oxide (NO) is a significant mediator of the effects of ADO on the pacemaker activity, or the underlying Ca2+ and K+ currents. 2. SAN pacemaker cells were isolated from rabbit hearts by enzymatic dispersion, and Ca2+ and K+ currents were recorded by the nystatin-perforated patch voltage clamp method. ADO was applied in the presence of the beta-adrenoceptor agonist, isopremaline (Iso) to mimic the adrenergic tone which the SAN is subjected to in vivo. 3. Control experiments confirmed that isolated SAN cells responded to ADO (10-100 microM) with the expected (i) small increase in background inwardly rectifying K+ current, IK-ADOi and (ii) pronounced decrease in L-type Ca2+ current, ICa-L. These effects were mimicked by a selective A1 purinoceptor agonist, N6-cyclopentyladenosine (CPA, 10 microM); and were inhibited following bath application of the antagonist, DPCPX (10 microM), which selectively blocks A1 purinoceptors. DMPX (10 microM), a blocker of A2 purinoceptor, had no effect on the actions of ADO. 4. A nitric oxide synthase inhibitor, L-NMMA (100 microM), abolished the inhibitory effect of ADO on ICa-L but did not alter activation of IK-ADO. After L-NMMA washoff, it was possible to obtain the normal response (inhibition) of ICa-L to ADO in the same cell. 5. To evaluate whether the observed effect of nitric oxide (NO) on ICa-L was mediated by an increase in guanylyl cyclase (GC) activity and cyclic GMP formation, the guanylyl cyclase inhibitor, LY 83583 (40 microM) was applied prior to ADO. Under these conditions, the inhibitory effect of ADO on ICa-L was abolished, but the activation of IK-ADO was still observed. 6. In combination, these findings strongly suggest that in mammalian primary pacemaker tissue which is under adrenergic tone, the effects of ADO on ICa-L are mediated by NO.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8968556      PMCID: PMC1915825          DOI: 10.1111/j.1476-5381.1996.tb16059.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  43 in total

Review 1.  Adenosine receptor subtypes: characterization and therapeutic regulation.

Authors:  M E Olah; G L Stiles
Journal:  Annu Rev Pharmacol Toxicol       Date:  1995       Impact factor: 13.820

Review 2.  Physiological roles for adenosine and adenosine 5'-triphosphate in the nervous system.

Authors:  T W Stone
Journal:  Neuroscience       Date:  1981       Impact factor: 3.590

Review 3.  Mechanisms of adenosine-mediated actions on cellular and clinical cardiac electrophysiology.

Authors:  W K Shen; Y Kurachi
Journal:  Mayo Clin Proc       Date:  1995-03       Impact factor: 7.616

4.  Nitric oxide synthase protects the heart against ischemia-reperfusion injury in rabbits.

Authors:  S Hoshida; N Yamashita; J Igarashi; M Nishida; M Hori; T Kamada; T Kuzuya; M Tada
Journal:  J Pharmacol Exp Ther       Date:  1995-07       Impact factor: 4.030

5.  Adenosine: electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardia.

Authors:  J P DiMarco; T D Sellers; R M Berne; G A West; L Belardinelli
Journal:  Circulation       Date:  1983-12       Impact factor: 29.690

Review 6.  Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes.

Authors:  L Belardinelli; J C Shryock; Y Song; D Wang; M Srinivas
Journal:  FASEB J       Date:  1995-03       Impact factor: 5.191

7.  LY83583: an agent that lowers intracellular levels of cyclic guanosine 3',5'-monophosphate.

Authors:  M J Schmidt; B D Sawyer; L L Truex; W S Marshall; J H Fleisch
Journal:  J Pharmacol Exp Ther       Date:  1985-03       Impact factor: 4.030

8.  Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes.

Authors:  P F Méry; C Pavoine; F Pecker; R Fischmeister
Journal:  Mol Pharmacol       Date:  1995-07       Impact factor: 4.436

9.  Adenosine A3 receptors regulate serotonin transport via nitric oxide and cGMP.

Authors:  K J Miller; B J Hoffman
Journal:  J Biol Chem       Date:  1994-11-04       Impact factor: 5.157

10.  Mechanism of the negative inotropic effect of adenosine in guinea pig atrial myocytes.

Authors:  D Wang; L Belardinelli
Journal:  Am J Physiol       Date:  1994-12
View more
  4 in total

1.  Muscarinic cholinergic regulation of cardiac myocyte ICa-L is absent in mice with targeted disruption of endothelial nitric oxide synthase.

Authors:  X Han; I Kubota; O Feron; D J Opel; M A Arstall; Y Y Zhao; P Huang; M C Fishman; T Michel; R A Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

2.  Altered cyclic nucleotide binding and pore opening in a diseased human HCN4 channel.

Authors:  Leo C T Ng; Yue Xian Li; Filip Van Petegem; Eric A Accili
Journal:  Biophys J       Date:  2022-02-24       Impact factor: 3.699

3.  Adenosine-mediated hypotension in in vivo guinea-pig: receptors involved and role of NO.

Authors:  P Nieri; E Martinotti; V Calderone; M C Breschi
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

4.  Nitroprusside modulates pulmonary vein arrhythmogenic activity.

Authors:  Yung-Kuo Lin; Yen-Yu Lu; Yao-Chang Chen; Yi-Jen Chen; Shih-Ann Chen
Journal:  J Biomed Sci       Date:  2010-03-20       Impact factor: 8.410

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.